سرطان الثدي منخفض HER2: المشهد المرضي والسريري

درس ترانتينو وآخرون هذه المسألة.

www.synapsesocial.com/papers/69daa8b54a1e15904c835852 — DOI: https://doi.org/10.1200/jco.19.02488

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.· 2018 · 63 citations
2. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges· 2019 · 296 citations
3. The HER2 Peptide Nelipepimut-S (E75) Vaccine (NeuVax™) in Breast Cancer Patients at Risk for Recurrence: Correlation of Immunologic Data with Clinical Response· 2014 · 72 citations
4. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study· 2019 · 557 citations
5. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study· 2020 · 808 citations